Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone and Bones Clear all
Completed Phase 2 Interventional Results available

A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

NCT01349101
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Fludarabine, Busulfan, Hematopoietic stem cell transplantation
Radiation · Drug · Genetic
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 19, 2026, 9:10 AM EDT
Terminated No phase listed Observational

Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)

NCT01293981
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
PureGen Osteoprogenitor Cell Allograft
Biological
Lead sponsor
Alphatec Spine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Beverly Hills, California • Middleton, Connecticut • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 19, 2026, 9:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

NCT03769467
View directory record Official record
Conditions
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia, Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Interventions
Tabelecleucel, Pembrolizumab
Biological
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Duarte, California • Palo Alto, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 19, 2026, 9:10 AM EDT
Recruiting No phase listed Observational

Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?

NCT03261544
View directory record Official record
Conditions
Sarcoma, Bone Metastases, Proximal Femur Replacement
Interventions
Proximal Femur Replacement
Procedure
Lead sponsor
Duke University
Other
Eligibility
16 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

NCT04663464
View directory record Official record
Conditions
Healthy Volunteers
Interventions
abaloparatide-sMTS, abaloparatide-SC
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 19, 2026, 9:10 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Preventing Infections in Orthopaedic Patients

NCT02948387
View directory record Official record
Conditions
Open Fracture
Interventions
Not listed
Lead sponsor
Olayemi Osiyemi MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 3 Interventional

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

NCT00172081
View directory record Official record
Conditions
Osteoporosis
Interventions
placebo, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
107
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Sitagliptin Umbilical Cord Blood Transplant Study

NCT00862719
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
Interventions
Sitagliptin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 19, 2026, 9:10 AM EDT
Active, not recruiting Phase 2 Interventional

MR-HIFU Treatment of Painful Osteoid Osteoma

NCT04658771
View directory record Official record
Conditions
Osteoid Osteoma
Interventions
MR-HIFU treatment
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
0 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 19, 2026, 9:10 AM EDT
Completed No phase listed Observational

Surveillance of Fungal Infections in Bone Marrow/Stem Cell and Organ Transplant Recipients

NCT00026767
View directory record Official record
Conditions
Fungus Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 19, 2026, 9:10 AM EDT
Active, not recruiting No phase listed Observational

Registry of Pediatric Orthopedic Trauma and Health Outcomes in Skeletally Immature Children

NCT04207892
View directory record Official record
Conditions
Long Bone Fractures
Interventions
Conservative (non-surgical) treatment, Surgical treatment
Procedure
Lead sponsor
AO Innovation Translation Center
Other
Eligibility
Up to 18 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Not applicable Interventional

Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

NCT01893892
View directory record Official record
Conditions
Musculoskeletal Complications
Interventions
levocarnitine, placebo, questionnaire administration
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 19, 2026, 9:10 AM EDT
Not listed Not applicable Interventional

Trinity™ BIOLOX Delta™ CoC THR Multi-center Study

NCT01921309
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, CDH
Interventions
Trinity CoC Total Hip System, Trinity Ceramic-on-Poly THR
Device
Lead sponsor
Corin
Industry
Eligibility
18 Years to 80 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Parker, Colorado • Hartford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

NCT02730312
View directory record Official record
Conditions
Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia, Blast Crisis
Interventions
XmAb14045
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Jacksonville, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Not applicable Interventional Results available

Prevention of Post Operative Bone Loss in Children

NCT00655681
View directory record Official record
Conditions
Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
Interventions
pamidronate, saline
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
4 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 19, 2026, 9:10 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis

NCT04670965
View directory record Official record
Conditions
Bone Loss
Interventions
E-PRF/rhBMP-2 (similar ratios), E-PRF/ACS/rhBMP-2, rhBMP-2/E-PRF, E-PRF only
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 9:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

NCT01966367
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions
CD34 Stem Cell Selection Therapy
Biological
Lead sponsor
Diane George
Other
Eligibility
Up to 40 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 19, 2026, 9:10 AM EDT
Withdrawn Phase 1 Interventional

Three Dosing Schedules of Oral Rigosertib in MDS Patients

NCT02075034
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 19, 2026, 9:10 AM EDT
Enrolling by invitation No phase listed Observational

Ostene in Thoracolumbar Decompression and Fusion Evaluated With VIBE

NCT06450834
View directory record Official record
Conditions
Intraoperative Complications, Intraoperative Bleeding, Intraoperative Blood Loss, Hemostasis, Blood Transfusion, Postoperative Hemorrhage, Postoperative Complications, Spine Fusion, Thoracolumbar Spine
Interventions
Ostene
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 19, 2026, 9:10 AM EDT
Completed No phase listed Observational

Misoprostol for Spinal Stenosis

NCT04611464
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Low Back Pain
Interventions
Misoprostol
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

NCT01243944
View directory record Official record
Conditions
Polycythemia Vera
Interventions
ruxolitinib tablets, Best Available Therapy (BAT)
Drug · Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
28
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Pomona, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

NCT00406393
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Interventions
Tacrolimus, Methotrexate, Sirolimus
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 60 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 19, 2026, 9:10 AM EDT
Completed No phase listed Observational

C-Type Natriuretic Peptide and Achondroplasia

NCT01541306
View directory record Official record
Conditions
Achondroplasia, Hypochondroplasia
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Months and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 19, 2026, 9:10 AM EDT
Completed No phase listed Observational

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

NCT00490906
View directory record Official record
Conditions
Multiple Sclerosis, Low Bone Density
Interventions
Copaxone, Interferon-beta 1a, Interferon-beta 1b
Drug
Lead sponsor
Nancy Hammond, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 19, 2026, 9:10 AM EDT